The DOI matches its Crossref record; 189 of the 189 references it cites were found in a registry or an index.
Bipolar depression: a major unsolved challenge
Open accessAbstract
Depression in bipolar disorder (BD) patients presents major clinical challenges. As the predominant psychopathology even in treated BD, depression is associated not only with excess morbidity, but also mortality from co-occurring general-medical disorders and high suicide risk. In BD, risks for medical disorders including diabetes or metabolic syndrome, and cardiovascular disorders, and associated mortality rates are several-times above those for the general population or with other psychiatric disorders. The SMR for suicide with BD reaches 20-times above general-population rates, and exceeds rates with other major psychiatric disorders. In BD, suicide is strongly associated with mixed (agitated-dysphoric) and depressive phases, time depressed, and hospitalization. Lithium may reduce suicide risk in BD; clozapine and ketamine require further testing. Treatment of bipolar depression is far less well investigated than unipolar depression, particularly for long-term prophylaxis. Short-term efficacy of antidepressants for bipolar depression remains controversial and they risk clinical worsening, especially in mixed states and with rapid-cycling. Evidence of efficacy of lithium and anticonvulsants for bipolar depression is very limited; lamotrigine has long-term benefit, but valproate and carbamazepine are inadequately tested and carry high teratogenic risks. Evidence is emerging of short-term efficacy of several modern antipsychotics (including cariprazine, lurasidone, olanzapine-fluoxetine, and quetiapine) for bipolar depression, including with mixed features, though they risk adverse metabolic and neurological effects.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In our pilot study, we have examined other clinical features reported in the literature to be associated with specific types of depression9,10,18,59,69, such as family history of bipolar disorder, number of previous depressive episodes, and other characteristics of depressive episodes. However, none of them could obtain performance comparable to course features (age of onset and disease duration),”
From Optimizing multi-domain hematologic biomarkers and clinical features for the differential diagnosis of unipolar depression and bipolar depression (2023) · doi:10.1038/s44184-023-00024-z · cites this paper as [18]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Efficacy of Ketamine in Bipolar Depression: Systematic Review and Meta-analysis Retracted
Parsaik, A. K., Singh, B., Khosh-Chashm, D., & Mascarenhas, S. S. (2015) · Journal of Psychiatric Practice · doi:10.1097/pra.0000000000000106 · Cited by 45
Retracted(1984) · The Lancet · doi:10.1016/s0140-6736(84)92810-1 · Cited by 2,925
Cross-national prevalence and risk factors for suicidal ideation, plans and attempts
Nock, M. K., Borges, G., Bromet, E. J., Alonso, J., Angermeyer, M., Beautrais, A., Bruffaerts, R., Chiu, W. T., de Girolamo, G., Gluzman, S., et al. (2008) · British Journal of Psychiatry · doi:10.1192/bjp.bp.107.040113 · Cited by 2,654
Risks of all-cause and suicide mortality in mental disorders: a meta-review
Chesney, E., Goodwin, G. M., & Fazel, S. (2014) · World Psychiatry · doi:10.1002/wps.20128 · Cited by 2,115
Yatham, L. N., Kennedy, S. H., Parikh, S. V., Schaffer, A., Bond, D. J., Frey, B. N., Sharma, V., Goldstein, B. I., Rej, S., Beaulieu, S., et al. (2018) · Bipolar Disorders · doi:10.1111/bdi.12609 · Cited by 1,852
Self-citationSuicide prevention strategies revisited: 10-year systematic review
Zalsman, G., Hawton, K., Wasserman, D., van Heeringen, K., Arensman, E., Sarchiapone, M., Carli, V., Höschl, C., Barzilay, R., Balazs, J., et al. (2016) · The Lancet Psychiatry · doi:10.1016/s2215-0366(16)30030-x · Cited by 1,765
Correll, C. U., Solmi, M., Veronese, N., Bortolato, B., Rosson, S., Santonastaso, P., Thapa‐Chhetri, N., Fornaro, M., Gallicchio, D., Collantoni, E., et al. (2017) · World Psychiatry · doi:10.1002/wps.20420 · Cited by 1,729
Meltzer, H. Y. (2003) · Archives of General Psychiatry · doi:10.1001/archpsyc.60.1.82 · Cited by 1,393
Epidemiology of suicide and the psychiatric perspective
Bachmann, S. (2018) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph15071425 · Cited by 1,377 · cited 1×
“By diagnosis, suicide risk ranks: bipolar disorders (BD-I = BD-II; especially with mixed or psychotic features) ≥ severe major depressive disorder with hospitalization > moderate depression among outpatients (Bachmann 2018; Hällgren et al.”
BackgroundGoodwin, G., Haddad, P., Ferrier, I., Aronson, J., Barnes, T., Cipriani, A., Coghill, D., Fazel, S., Geddes, Jr., Grunze, H., et al. (2016) · Journal of Psychopharmacology · doi:10.1177/0269881116636545 · Cited by 1,309
Research works printed but not linked: 5
- Fountoulakis KN, Vieta E, Young A, et al. Unmet needs in the treatment of bipolar disorder and recommendations for future research. Int J Neuropsychopharmacol. 2017;20(2):196–205.
- Laughren TP. Proceedings of a meeting of the Psychopharmacology Drug Advisory Committee (PDAC) concerning suicidal risk in trials of antidepressant drugs in juvenile and adult patients, 2006. http://www.fda.gov/ohrms/dockets/ac/06/briefing//2006-4272b1-01-fda.pdf. Accessed 22 Dec 2018.
- Müller-Oerlinghausen B, Ahrens B, Felber W. Suicide-preventive and mortality-reducing effect of lithium. In: Bauer M, Grof P, Müller-Oerlinghausen B, editors. Lithium in neuropsychiatry. London: Informa Healthcare; 2006. p. 79–192.
- Simon RI, Hales RE, editors. Textbook of suicide assessment and management. 2nd ed. Washington, DC: American Psychiatric Press; 2012.
- Vázquez GH, Forte A, Camino S, Tondo L, Baldessarini RJ. Chapt 17: Psychiatric comorbidity in bipolar disorder: treatment implications: anxiety syndromes and substance abuse. In: Carvalho E, Vieta E, editors. The treatment of bipolar disorder: integrative treatment strategies and future directions. New York: Oxford University Press; 2017b. p. 225–54.
Cited by
Lithium Treatment Over the Lifespan in Bipolar Disorders
Volkmann, C., Bschor, T., & Köhler, S. (2020) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2020.00377 · Cited by 145
Yildiz, A., Siafis, S., Mavridis, D., Vieta, E., & Leucht, S. (2023) · The Lancet Psychiatry · doi:10.1016/s2215-0366(23)00199-2 · Cited by 104
Nestsiarovich, A., Gaudiot, C., Baldessarini, R. J., Vieta, E., Zhu, Y., & Tohen, M. F. (2021) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2021.08.264 · Cited by 105
Self-citationLithium’s antiviral effects: a potential drug for CoViD-19 disease?
for the International Group for The Study of Lithium Treated Patients (IGSLi), Murru, A., Manchia, M., Hájek, T., Nielsen, R. E., RYBAKOWSKI, J. K., Sani, G., Schulze, T. G., Tondo, L., & Bauer, M. (2020) · International Journal of Bipolar Disorders · doi:10.1186/s40345-020-00191-4 · Cited by 89
“2016), and is associated with an excess of mortality (Baldessarini et al. 2020).”
BackgroundSelf-citationMedeiros, G. C., Gould, T. D., Prueitt, W. L., Nanavati, J., Grunebaum, M. F., Farber, N. B., Singh, B., Selvaraj, S., Machado-Vieira, R., Achtyes, E. D., et al. (2022) · Molecular Psychiatry · doi:10.1038/s41380-022-01652-1 · Cited by 75
“Even when effective, conventional treatments may take weeks to provide significant symptomatic relief [5, 6], extending the personal and social burden of depression and increasing risk of negative consequences such as suicide [7].”
Background
Metadata
- Authors
- Baldessarini, R. J., Vázquez, G. H., & Tondo, L.
- Affiliations
- Harvard University (US)
- Queen's University (CA)
- Corresponding author
- Baldessarini, Ross J.
- Venue
- International Journal of Bipolar Disorders
- Published
- 2020-01-06
- Volume
- 8
- Issue
- 1
- Pages
- 1-1
- ISSN
- 2194-7511 (ISSN-L)
- PMC
- PMC6943098
- OpenAlex
- W3000431195
- Semantic Scholar
- fbdec026b50c3a43fa774eaba7baec2f5d05aa8e
- Cited by
- 235
- References
- 189
- Citations by year
- 2026: 29 · 2025: 36 · 2024: 36 · 2023: 42 · 2022: 38 · 2021: 33 · 2020: 20
- FWCI
- 5.50
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- cc-by
- creativecommons.org/licenses/by/4.0 (tdm)
- creativecommons.org/licenses/by/4.0 (vor)
- Locations
- International Journal of Bipolar Disorders (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion)
- Funders
- Bruce J Anderson Foundation
- Topics
- Health Sciences › Medicine › Psychiatry and Mental health › Bipolar Disorder and Treatment
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Social Sciences › Psychology › Clinical Psychology › Personality Disorders and Psychopathology
- Keywords
- bipolar depression, bipolar disorder, suicide risk, mixed states, rapid cycling, antidepressant-induced mania, lithium, lamotrigine, antiepileptic drugs, antipsychotic drugs, cariprazine, lurasidone, quetiapine, teratogenicity, valproic acid, carbamazepine, mortality
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Bipolar depression: a major unsolved challenge. https://app.cochat.ai/papers/10.1186/s40345-019-0160-1
- The paper
- Baldessarini, R. J., Vázquez, G. H., & Tondo, L. (2020). Bipolar depression: a major unsolved challenge. International Journal of Bipolar Disorders. https://doi.org/10.1186/s40345-019-0160-1
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.